These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30418214)

  • 1. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.
    Huhn AS; Strain EC; Bigelow GE; Smith MT; Edwards RR; Tompkins DA
    Anesthesiology; 2019 Jan; 130(1):131-141. PubMed ID: 30418214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ascending buprenorphine doses on measures of experimental pain: A pilot study.
    Nielsen S; Rivas C; Demirkol A; Lintzeris N
    J Subst Abuse Treat; 2019 Sep; 104():128-134. PubMed ID: 31370976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.
    Agin-Liebes G; Huhn AS; Strain EC; Bigelow GE; Smith MT; Edwards RR; Gruber VA; Tompkins DA
    Drug Alcohol Depend; 2021 Sep; 226():108869. PubMed ID: 34216862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
    Greenwald MK; Sogbesan T; Moses TEH
    Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of buprenorphine in buprenorphine-maintained volunteers.
    Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
    Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
    Murnion BP; Rivas C; Demirkol A; Hayes V; Lintzeris N; Nielsen S
    Pain Med; 2020 Jun; 21(6):1188-1198. PubMed ID: 31504868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on mood, opioid adverse effects, and recovery.
    Yang Y; Wu J; Li H; Ye S; Xu X; Cheng L; Zhu L; Peng Z; Feng Z
    BMC Anesthesiol; 2018 Apr; 18(1):37. PubMed ID: 29636011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.
    Duke AN; Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2010 Aug; 211(3):303-12. PubMed ID: 20577717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.
    Dunn KE; Bergeria CL; Huhn AS; Speed TJ; Mun CJ; Vandrey R; Campbell CM
    Neuropsychopharmacology; 2021 Jul; 46(8):1451-1459. PubMed ID: 33879842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
    Strain EC; Stoller K; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers.
    Coe MA; Nuzzo PA; Lofwall MR; Walsh SL
    J Pain; 2017 Jul; 18(7):825-834. PubMed ID: 28274698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of intravenous administration of hydromorphone hydrochloride alone or followed by buprenorphine hydrochloride or butorphanol tartrate to healthy conscious cats.
    Simon BT; Steagall PV; Monteiro BP; Troncy E; Lizarraga I
    Am J Vet Res; 2016 Mar; 77(3):245-51. PubMed ID: 26919594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.